API and IP Newsletter: 1.) DMF filings in March 2025 2.) Baxter Healthcare Corporation Vs Nevakar Injectables, Inc. – Norepinephrine composition
Contents Recent DMF filings- March 2025 General information Gilead Sciences to pay $202 million in US settlement over HIV drug kickbacks Satsuma Pharmaceuticals Announces U.S. FDA Approval for Atzumi™ (Dihydroergotamine) Nasal Powder for the Acute Treatment of Migraine Intellectual Property Baxter Healthcare Corporation Vs Nevakar Injectables, Inc. – Norepinephrine composition Recent DMF filings- March 2025 We track DMFs filed each month. The FDA publishes the list of DMF filings quarterly. The first quarter DMF filing list was released in the first week of April, and this week we are analysing DMFs filed in March 2025. A total of 339 DMFs were filed in March 2025. The top DMF filers are listed below. This number significantly exceeds the average monthly DMF filings. Some of our other observations are as follows. General information Gilead Sciences to pay $202 million in US settlement over HIV drug kickbacks Gilead Sciences agreed to pay $202 million to settle a whistleblow...